HOME
CAREERS
CONTACT US
KOREAN
ENGLISH
KR
EN
Toggle navigation
COMPANY
ABOUT US
KEY MEMBERS
HISTORY
BOARD OF DIRECTORS
SCIENTIFIC ADVISORY BOARD
SCIENCE
NT-I7
NeoBase
NT2020
NT3020
NT4010
NT5010
PIPELINE
Clinical
R&D
COLLABORATION
INVESTORS
NOTICE
PRESENTATION
GENERAL MEETING
OF STOCKHOLDERS
INDEPENDENT
AUDITOR'S REPORT
CONTACT IR
MEDIA
NEWS
VIDEO SOURCE
ESG
OVERVIEW
ENVIRONMENTAL
SOCIAL
GOVERNANCE
NEWS
HOME
MEDIA
NEWS
NEWS
All
Press Release
News Update
Quarterly update
Total
86
46
Press Release
NeoImmuneTech Announces First Patient Dosed in Phase 1b Study of NT-I7 (efineptakin alfa) and Kymriah® (tisagenlecleucel) in Relapsed/Refractory Large B-Cell Lymphoma
2021-10-13
45
Press Release
NeoImmuneTech to Present Three Posters at Society for Immunotherapy of Cancer Annual Meeting
2021-10-05
44
Press Release
NeoImmuneTech to Present at Society for Neuro-Oncology Annual Meeting
2021-09-03
43
Press Release
NeoImmuneTech Appoints Jean Fan, M.D., as Chief Clinical Officer
2021-08-25
42
Press Release
NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1 Study of NT-I7 (efineptakin alfa) for the Treatment of Kaposi Sarcoma in Patients With or Without HIV Infection
2021-07-26
41
Press Release
NeoImmuneTech Trial Data Presented at American Society of Clinical Oncology Annual Meeting
2021-06-08
40
Press Release
NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)
2021-06-08
39
Press Release
NeoImmuneTech Announces First Patient Dosed in the Pilot Study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy
2021-05-25
38
Press Release
NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting
2021-05-20
37
Press Release
NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) in Patients with High Grade Glioma
2021-03-30
1
2
3
4
5
>
>>
Search